ロード中...
Patient Characteristics and Prescribing Patterns Associated with Sofosbuvir Treatment for Chronic HCV Infection in a Commercially Insured Population
BACKGROUND: In December 2013, the US Food and Drug Administration (FDA) approved sofosbuvir (Sovaldi) for the treatment of patients with chronic hepatitis C virus (HCV) infection. Given the potential “warehousing” of patients before the launch of sofosbuvir and the possibility that some patients and...
保存先:
| 出版年: | Am Health Drug Benefits |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Engage Healthcare Communications, LLC
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4856232/ https://ncbi.nlm.nih.gov/pubmed/27182426 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|